Publications by authors named "Elisabeth Fritzke Emdal"
Correction: Associations between detectable circulating tumor DNA and tumor glucose uptake measured by F-FDG PET/CT in early-stage non-small cell lung cancer.
BMC Cancer
July 2023
Article Synopsis
- The study explores the relationship between circulating tumor DNA (ctDNA) levels and tumor metabolic activity in early-stage non-small cell lung cancer (NSCLC) patients, aiming to find independent prognostic indicators.
- A total of 63 patients undergoing treatment had their glucose uptake measured through F-FDG PET/CT scans, showing significant differences in tumor metrics between those with and without detectable ctDNA.
- Results indicate that higher ctDNA quantities correlate with greater metabolic tumor volume (MTV) and total lesion glycolysis (TLG), suggesting that ctDNA levels could provide important prognostic information for patient outcomes.
(1) Background: Analysis of tumor DNA by next-generation sequencing (NGS) plays various roles in the classification and management of cancer. This study aimed to assess the performance of two similar and large, comprehensive gene panels with a focus on clinically relevant variant detection and tumor mutation burden (TMB) assessment; (2) Methods: DNA from 19 diagnostic small cell lung cancer biopsies and an AcroMetrix™ assessment sample with >500 mutations were sequenced using Oncomine™ Comprehensive Assay Plus (OCAP) on the Ion Torrent platform and TruSight Oncology 500 Assay (TSO500) on the Illumina platform; (3) Results: OCAP and TSO500 achieved comparable NGS quality, such as mean read coverage and mean coverage uniformity. A total of 100% of the variants in the diagnostic samples and 80% of the variants in the AcroMetrix™ assessment sample were detected by both panels, and the panels reported highly similar variant allele frequency.
View Article and Find Full Text PDFIntroduction: Studies have indicated that detection of mutated KRAS or EGFR in circulating tumor DNA (ctDNA) from pre-treatment plasma samples is a negative prognostic factor for non-small cell lung cancer (NSCLC) patients. This study aims to investigate whether this is the case also for NSCLC patients with other tumor mutations.
Methods: Tumor tissue DNA from 107 NSCLC patients was sequenced and corresponding pre-treatment plasma samples were analyzed using a limited target next-generation sequencing approach validated in this study.
Background: due to emerging therapeutics targeting G12C and previous reports with conflicting results regarding the prognostic impact of and G12C in non-small cell lung cancer (NSCLC), we aimed to investigate the frequency of mutations and their associations with clinical characteristics and outcome. Since mutation subtypes have different preferences for downstream pathways, we also aimed to investigate whether there were differences in outcome according to mutation preference for the Raf, PI3K/Akt, or RalGDS/Ral pathways.
Methods: retrospectively, clinicopathological data from 1233 stage I-IV non-squamous NSCLC patients with known status were reviewed.